Indaptus Therapeutics is trading 5.04% lower at $2.26, with no verified October 5 announcement or confirmed catalyst explaining the decline. - The latest company-specific items located were an August 31 filing for an offering and a September 1 amended ATM agreement; neither was new October 5 news. - Supplied market indicators are mixed, and the available evidence does not establish a specific reason for the price change.